<DOC>
	<DOCNO>NCT00815971</DOCNO>
	<brief_summary>Recently suggest specific mutation EGFR gene lung cancer patient associate response novel drug target EGF system . Recent research also indicate possible association degree aggressiveness disease . The importance mutation controversial , data base small study highly select patient . In project investigator want study type frequency EGFR mutation untreated treated patient systematic manner relate survival . The thorough registration patient data DK enable u create strong The investigator expect knowledge great importance future rational use drug target EGF receptor .</brief_summary>
	<brief_title>Mutations Epidermal Growth Factor Receptor ( EGFR ) Gene Non-Small Cell Lung Carcinoma ( NSCLC ) Relation Response Treatment With Erlotinib</brief_title>
	<detailed_description>Aim : 1 . To establish method identify mutation EGFR gene small clinical sample lung cancer patient . 2 . In retrospective study ( n=500 ) relate survival frequency type mutation EGFR gene Danish population patient advance , inoperable non small cell lung cancer ( NSCLC ) diagnose prior introduction treatment direct towards EGFR . 3 . In prospective study ( n=300 ) , identify mutation EGFR gene patient treat erlotinib , tyrosine kinase inhibitor target EGFR . Presence mutation related expression part EGF system , mutation gene cod K-RAS treatment response .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients start treatment erlotinib sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>EGFR mutation</keyword>
	<keyword>EGFR inhibitor</keyword>
	<keyword>erlotinib</keyword>
</DOC>